secwatch.observer — SEC 8-K summary
======================================

Issuer:     Poseida Therapeutics, Inc. (—)
CIK:        0001661460
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059522
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Poseida Q1 rev $28.1M, net loss $24.3M; Astellas $50M upfront collab, new CMO
-----------------------------------------------------------------------------

- Revenue $28.1M vs $10.3M YoY; net loss $24.3M vs $38.8M; cash $198.6M, runway into H2 2025.
- Astellas research collaboration: $50M upfront, up to $550M milestones, low double-digit royalties for solid tumor CAR-T.
- Roche partnership: $30M milestone in Q1, $15M expected May 2024; total $95M in 2024 milestones/upfront.
- P-BCMA-ALLO1 data: 60% overall response rate in RRMM patients after prior BCMA-directed therapy.
- Appointed Syed Rizvi, M.D., as Chief Medical Officer in April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/0000950170-24-059522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/pstx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer